The CNPV program aims to reduce drug review times to 1-2 months, raising concerns about safety and regulatory scrutiny. Critics argue that accelerated timelines may lead to safety issues and strain ...
Type C Meeting with US FDA set for December 11, 2025 to address key items following August 27, 2025 End of Phase 2 Meeting ...
PRO Real Estate Investment Trust ("PROREIT" or the "REIT") (TSX: PRV.UN) announced today that a cash distribution of $0.0375 per trust unit of the REIT for the month of November 2025 ($0.45 on an ...
Venezuela's National Assembly on Thursday approved a 15-year extension of the joint ventures between state company PDVSA and ...
Two years after buying CinCor Pharma for $1.3 billion, AstraZeneca has reported that the main asset in the deal, for uncontrolled or treatment-resistant hypertension, has cleared a phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback